What's in MISSION PHARMA's pipeline?

MISSION PHARMA has 2 drugs in our index: 2 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with MISSION PHARMA's portfolio?

Top competitors by shared drug class: , Baxter, Evofem Inc, Sanofi.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/mission-pharma.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-06-10 · How we verify

MISSION PHARMA — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

MISSION PHARMA pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Tindamax	TINIDAZOLE	marketed	Nitroimidazole Antimicrobial [EPC]		Infectious Disease	2004-01-01
Lithostat	ACETOHYDROXAMIC ACID	marketed	Urease Inhibitor [EPC]	Carbonic anhydrase 2	Infectious Disease	1983-01-01

Therapeutic area mix

Infectious Disease · 2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

· 1 shared drug class
Baxter · 1 shared drug class
Evofem Inc · 1 shared drug class
Sanofi · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for MISSION PHARMA:

Cite this brief

Drug Landscape (2026). MISSION PHARMA — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/mission-pharma. Accessed 2026-06-10.